| Document |
Document Title |
|
WO/2019/090076A1 |
Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases; disorders and conditions.
|
|
WO/2019/080226A1 |
The present invention belongs to the technical field of pesticides, and involves more specifically a substituted benzonitril diketone compound or a tautomer, a salt thereof, a preparation method therefor, a herbicide, and an application ...
|
|
WO/2019/081485A1 |
The invention relates to substituted pyrazoles of general formula (I) or salts thereof, wherein the groups of general formula (I) are defined as cited in the description, and to the use thereof as herbicides, in particular for controllin...
|
|
WO/2019/080225A1 |
Provided are a pyrazolone compound or salt thereof, a herbicide composition and a use. The pyrazolone compound is represented by general formula I:, where R1R2N represents, where Het is selected from a five- or six-membered heterocyclic ...
|
|
WO/2019/081477A1 |
The invention relates to substituted pyrazoles of general formula (I) or salts thereof, wherein the groups of general formula (I) are defined as cited in the description, and to the use thereof as herbicides, in particular for controllin...
|
|
WO/2019/077174A1 |
The invention relates to three families of amines derived from 5-nitroindazole [1-(aminoalkyl)indazolinones, 3-(aminoalkoxy) indazoles and 3-(alkylamino)indazoles] that have antiprotozoal properties, and to the use thereof for the produc...
|
|
WO/2019/079119A1 |
In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured: wherein the variables shown in Formula AA can be as defined anywhere herein. Compounds AA are modulators of NLRP1 and/or NLRP3
|
|
WO/2019/071348A1 |
There is provide an extended release dosage form comprising a release modifying excipient comprising high amylose starch, cross-linked hydroxypropylated amylopectin, and a pre-gelatinized common starch; wherein the release modifying exci...
|
|
WO/2019/073052A1 |
The invention relates to a salt of 3-methyl-1 -phenyl-2-pyrazolin-5-one (edaravone), wherein the salt is 3-methyl-1 -phenyl-2-pyrazolin-5-one napadisylate or 3-methyl-1 -phenyl-2- pyrazolin-5-one hemi-napadisylate. These napadisylate sal...
|
|
WO/2019/074979A1 |
Heterocyclic compounds as Weel inhibitors are provided. The compounds may find therapeutic agents for the treatment of diseases and may find particular use in oncology.
|
|
WO/2019/068772A1 |
The present invention relates to compounds of formula (I): wherein Q is selected from O or S; R1 is a saturated or unsaturated hydrocarbyl group, wherein the hydrocarbyl group may be straight-chained or branched, or be or include cyclic ...
|
|
WO/2019/071111A1 |
Solid state forms of Eltrombopag choline, processes for preparation thereof and pharmaceutical compositions thereof are disclosed.
|
|
WO/2019/064139A1 |
A continuous process for the manufacture of celecoxib includes reacting a stream of a first solution of 4'-methylacetophenone in a first organic solvent and a stream of a second solution of ethyl trifluoroacetate in a second organic solv...
|
|
WO/2019/063696A1 |
The invention relates to primary para-phenylenediamine compounds substituted with an aliphatic chain comprising a cationic heterocyclic group according to formula (I), as well as the organic or mineral acid or base addition salts thereof...
|
|
WO/2019/061324A1 |
The invention relates to crystalline forms of a 3-substituted 1, 2, 4-oxadiazole compound, including an anhydrous crystalline form, methods of their preparation, and related pharmaceutical preparations thereof. The invention also relates...
|
|
WO/2019/060260A1 |
The present disclosure relates to certain compounds having binding affinity for XPA, and uses thereof. Specifically, the present disclosure relates to the use of XPA inhibitors as described herein in in methods of treating cancer.
|
|
WO/2019/058885A1 |
Provided is a method for producing a compound, by which a sulfonate salt of a hydrazine compound is able to be safely produced with high yield. Also provided is a method for producing a compound, by which an acid hydrazide compound deriv...
|
|
WO/2019/057946A1 |
Multi-cyclic aromatic compounds and methods of use as Factor D modulators are described herein.
|
|
WO/2019/056123A1 |
Pharmaceutical compositions comprising one or more cannabinoids and a pharmaceutically acceptable carrier are disclosed. The compositions are in a form suitable for topical administration, and are useful in the treatment of pain. The can...
|
|
WO/2019/056120A1 |
The present application relates to sulfonamide containing compounds of Formulae (I) and (II) and compositions containing said compounds effective in the treatment of cell proliferative disorders, in particular cancer, and various methods...
|
|
WO/2019/054944A1 |
The present invention relates to compounds of general Formula (I), and/or tautomers, enantiomers, solvates, hydrates, and pharmaceutically acceptable salts thereof. The present invention also relates to compounds of Formula (I) for use i...
|
|
WO/2019/055540A1 |
A compound of Formula (Ia) or (Ib), or a pharmaceutically acceptable salt thereof is described, wherein the substituents are as defined herein. Pharmaceutical compositions comprising the same and method of using the same are also described.
|
|
WO/2019/054430A1 |
The purpose of the present invention is to provide a compound having an anti-inflammatory action, a pharmacologically acceptable salt thereof, etc. A solving means of the present invention is a compound of general formula (1) or a pharma...
|
|
WO/2019/053634A1 |
The invention discloses compounds of Formula (I), wherein A1, R1, R2, R3, R4, and n are as defined herein. The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharma...
|
|
WO/2019/051199A1 |
Disclosed are compounds of Formula (I), methods of using the compounds for inhibiting HPK1 activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or d...
|
|
WO/2019/047826A1 |
An aromatic derivative as represented by formula (I), a pharmaceutically acceptable salt thereof or a pharmaceutical composition comprising same, a preparation method therefor, and uses of the aromatic derivative and the pharmaceutically...
|
|
WO/2019/051396A1 |
Disclosed herein are compounds having a structure of formula (I), compositions and methods useful for the treatment of a disease or infection, such as a viral infection (e.g., Ebola), cancer and obesity: formula (I), wherein A is N or CR...
|
|
WO/2019/045035A1 |
The present invention relates to biaryloxy derivatives which have blocking activities of voltage gated sodium channels as the TTX-S channels, and which are useful in the treatment or prevention of disorders and diseases in which voltage ...
|
|
WO/2019/043372A1 |
There are described compounds of formula (I) in which X, R1, R2 and n are each as herein defined; and their use as a medicament in the treatment of conditions involving abnormal activation and/or malfunction of the hedgehog pathway, such...
|
|
WO/2019/044266A1 |
A method for producing a pyrazole-4-carboxamide derivative by subjecting a pyrazole-4-carboxylic acid ester and an amine to an aminolysis reaction in a solvent in the presence of a base, the method being characterized in that the reactio...
|
|
WO/2019/046467A1 |
The invention provides compounds of formula (I): and salts thereof wherein R1-R5 have any of the meanings described in the specification. The compounds are useful for treating bacterial infections (e.g. tuberculosis).
|
|
WO/2019/041340A1 |
A compound of formula (I) or a pharmaceutical salt thereof, use, methods for its preparation are described.
|
|
WO/2019/039290A1 |
Provided are: an actinic ray-sensitive or radiation-sensitive resin composition that has excellent resolution, exposure latitude, and pattern shape properties; and a resist film, a pattern-forming method, a method for producing an electr...
|
|
WO/2019/040319A1 |
Provided are methods and compositions for prolonging survival and/or reducing or inhibiting tumor growth in a cancer subject receiving a regimen of one or more chemotherapeutic agents, an inhibitor of soluble epoxide hydrolase (sEHi) and...
|
|
WO/2019/034686A1 |
The present invention relates to compounds of formula (I): Formula (I) wherein Q is selected from O or S; R1 is a saturated or unsaturated, optionally substituted hydrocarbyl group optionally including one or more heteroatoms N, O or S; ...
|
|
WO/2019/033590A1 |
Disclosed are a substituted benzoyl cyclohexanedione compound or a tautomer and salt thereof, a preparation method therefor, a herbicidal composition and the use. The substituted benzoyl cyclohexanedione compound or a tautomer and salt t...
|
|
WO/2019/034690A1 |
The present invention relates to sulfonylureas and sulfonylthioureas comprising a 5-membered nitrogen-containing heteroaryl ring attached to the sulfonyl group, wherein the heteroaryl ring is substituted with a nitrogen-containing group ...
|
|
WO/2019/034688A1 |
The present invention relates to sulfonylureas and sulfonylthioureas comprising a 5-membered heteroaryl group substituted with an amide-containing group. The present invention further relates to salts, solvates and prodrugs of such compo...
|
|
WO/2019/034692A1 |
The present invention relates to sulfonylureas and sulfonylthioureas comprising a 5-membered heteroaryl ring attached to the sulfonyl group, wherein the heteroaryl ring is di-substituted at the 3- and 4-positions relative to the point of...
|
|
WO/2019/033068A1 |
Disclosed herein are methods of using a 5-HT2A serotonin receptor inverse agonist for the prophylaxis and/or treatment of psychosis or psychotic symptoms in an individual comprising administering to said individual in need thereof a ther...
|
|
WO/2019/030358A1 |
Compounds of formula (I) as defined herein, to processes for preparing them, to pesticidal, in particular insecticidal, acaricidal, molluscicidal and nematicidal compositions comprising them and to methods of using them to combat and con...
|
|
WO/2019/028689A1 |
The present invention relates to a crystalline form of N-((S)-1-(3-(3-chloro-4-cyanophenyl)-1H-pyrazol-1-yl)prop-2-
yl)-5-(1-hydroxylethyl)-1H-pyrazole-3-carboxamide (namely, ODM-201). The ODM-201 crystalline form of the present inventio...
|
|
WO/2019/025467A1 |
The present disclosure relates to compounds of Formula (I): (I); and to their pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful fo...
|
|
WO/2019/023147A1 |
In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured.The variables shown in Formula AA are as defined in the claims. The compounds of formula AA are NLRP3 activity modulators and, as such, c...
|
|
WO/2019/022179A1 |
To provide a heterocyclic compound which can exhibit an antagonistic action to NR2B subunit-containing NMDA receptors and, therefore, is expected to be useful as a prophylactic or therapeutic agent for major depression, bipolar disorder,...
|
|
WO/2019/023145A1 |
In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured. The variables shown in Formula AA are as defined in the claims. The compounds of formula AA are NLRP3 activity modulators and, as such, ...
|
|
WO/2019/020726A1 |
The invention discloses a method for preparation of alkylated, fluoro alkylated, chloro alkylated and fluorochloro alkylated compounds by a heterogeneous Co-catalysed alkylation or fluoro, chloro and fluorochloro alkylation with alkyl ha...
|
|
WO/2019/023553A1 |
The present disclosure relates to bifunctional compounds, which find utility to degrade (and inhibit) Androgen Receptor. In particular, the present invention is directed to compounds, which contain on one end a VHL ligand which binds to ...
|
|
WO/2019/016069A1 |
The invention relates to substituted 5-(Het-)arylpyrazolamides of general formula (I) and to the their use as herbicides, in particular for controlling weeds and/or weed grasses in crops of useful plants and/or as plant growth regulators...
|
|
WO/2019/018536A1 |
Provided here are compositions containing a conjugate of a label, a chelator, and a cannabinoid analog and methods for diagnosing, treating, or monitoring the progression of a cancer or a neurologic disorder using these compositions. Als...
|
